RNAimmune

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics. Inimmune was founded in early 2016 by Drs. Inimmune was formed from an experienced, close-knit team of biotech/pharmaceutical industry professionals. Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Our goal at Inimmune is to recruit, hire, and maintain a diverse workforce. At Inimmune our team is advancing the next generation of immunotherapies and vaccine technology for the benefit of human kind. The group has extensive expertise in synthetic and process chemistry, drug formulation, and immunology. Our pipeline includes innovative new treatments to harness the innate immune system in areas of critical patient need such as oncology, allergic rhinitis, food allergy, infectious disease vaccines, and novel antibiotics for bacterial infections.

ImmunityBio gains $300 million in non-dilutive capital for commercialization and pipeline expansion efforts. ImmunityBio is developing immunotherapy products and cell therapies for cancer that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. ImmunityBio is working with the National Cancer Institute (NCI) on the largest Lynch syndrome cancer prevention study in the U.S. ImmunityBio’s platforms address the entire immune system, harnessing the power of both innate and adaptive functions of the immune system by activation of ‘first responder’ natural killer (NK) cells, T cells, and macrophages, and establishment of immune memory by dendritic cells. We are also leveraging our established neoepitope prediction pipeline to predict which unique tumor-associated neoepitope peptides have the potential to trigger an effective, anti-tumor immune response when delivered to patients as a personalized vaccine. We are applying our science and platforms, including the development of potential cancer vaccines, to treat cancers, as well as developing immuno- and cell therapies that we believe could sharply reduce or eliminate the need for standard high-dose chemotherapy. Our investigational immunotherapy products are tailored to each patient’s needs. We employ a “triangle” offense designed to deliver durable, complete responses in cancer and infectious diseases.

We are a cross-disciplinary group of entrepreneur-scientists that came together in 2020 to usher in the next generation of RNA technologies. In addition, we are partnering with leading institutions, including the Vaccine Research Center at the NIAID, Cambridge University, Twist Biosciences, and Biotage. Coming from leading academic institutions, well-established pharma companies, and high-stress military environments, we share the single goal of creating scalable processes to program RNA therapies, focusing initially on treating respiratory diseases.

Findimmune is a Gustave Roussy's spin-off company developing anticancer and immune therapies, based in France. Findimmune develops lead candidates for the treatment of cancer, based on immune stimulation for anticancer vaccination and on the conversion of unresponsive “cold” tumors into sensitive “hot” tumors as part of anti-cancer treatments. Findimmune also works on the delivery of innovative drugs in combination with immune checkpoint inhibitors. Findimmune benefits from a drug discovery research platform (UMR-S 1030 INSERM) in partnership with the Gustave Roussy Cancer Campus, France, where FindImmune is headquarted. It focuses on the identification of novel therapies dedicated to the manipulation of macrophage immune checkpoints that were recently discovered and patented for both anticancer and inflammatory diseases. Because patient outcomes is our primary motivation, relying on disruptive science and innovative therapeutic development, Findimmune is committed to identify and develop new drugs which will benefit quickly a patient population suffering from cancer. Because pharmaceutical development is a complex environment with strict rules that aim to protect patients from potential hazards of drugs, our team combines complementary expertises. We believe our development pipeline and clinical programs to create innovative medicines for a wide range of diseases and conditions will play a major role in a very next future.

Baseimmune is a discovery stage biotech company focused on antigen discovery and vaccine development. Baseimmune is solving this major technological roadblock by improving and accelerating the design of mutation-proof antigens that can be combined with any delivery system such as mRNA, DNA or viral vectors to create highly efficacious and cross-protective vaccines. Baseimmune’s deep learning algorithm integrates genomic, epidemiological, immunological, clinical and evolutionary data together to create artificial antigens drawn from the entire pathogen’s genome, rather than a single protein. As the CEO of Baseimmune, Josh is responsible for company strategy and technology development. Prior to Baseimmune, Ariane was a postdoctoral researcher at the University College London working on stablishing protective antigens in a vaccine against Cytomegaloviruses. As the CSO of Baseimmune, Ariane is responsible for scientific strategy, company strategy, and operations. As the CTO of Baseimmune, Phil is responsible for platform and database development that underpins Baseimmune’s core technology. Meet the Baseimmune team and find out what we do.

We’re a clinical stage biotech co-founded by the Nobel scientist who discovered RNA interference. Our proprietary INTASYL technology is a platform for self-delivering RNAi immuno-oncology therapies.